Special Issue

Novel Challenges and Advances in Lung Cancer

Message from the Guest Editor

Lung cancer remains the leading cause of cancer-related deaths worldwide. It is often diagnosed after it has reached an advanced stage, and its delayed diagnosis significantly worsens the patient's prognosis. Even though, in recent years, we have observed significant progress in both diagnostics and therapy, the results of treatment in advanced disease are still unsatisfactory. In this Special Issue, we welcome both original research articles and reviews. The aim is to present the most up-to-date and cutting-edge studies into the mechanisms contributing to the development and progression of lung cancer.

Guest Editor

Dr. Michał Szczyrek

Department of Pneumology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland

Deadline for manuscript submissions

closed (5 June 2024)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/192643

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

